DDInter1852 DDInter1266
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. It is available in the following routes of administration: subcut
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) resembles {v} (Compound) Naproxen
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} (Compound) resembles {v} (Compound) Naproxen
Treprostinil {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Naproxen
Treprostinil {u} (Compound) upregulates {v} (Gene) FAM63A
FAM63A {u} (Gene) is upregulated by {v} (Compound) Naproxen
Treprostinil {u} (Compound) upregulates {v} (Gene) CANT1
CANT1 {u} (Gene) is downregulated by {v} (Compound) Naproxen
Treprostinil {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Naproxen
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Naproxen
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabumetone
Nabumetone {u} (Compound) resembles {v} (Compound) Oxybenzone
Oxybenzone {u} (Compound) resembles {v} (Compound) Naproxen
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Naproxen
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} (Compound) resembles {v} (Compound) Agomelatine
Agomelatine {u} (Compound) resembles {v} (Compound) Naproxen
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) resembles Naproxen (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Naproxen (Compound)
Treprostinil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Naproxen (Compound)
Treprostinil (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) is upregulated by Naproxen (Compound)
Treprostinil (Compound) upregulates CANT1 (Gene) and CANT1 (Gene) is downregulated by Naproxen (Compound)
Treprostinil (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Naproxen (Compound)
Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Naproxen (Compound) and PTGS2 (Gene) is upregulated by Naproxen (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone and Nabumetone (Compound) resembles Oxybenzone (Compound) and Oxybenzone (Compound) resembles Naproxen (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Suprofen (Compound) and Suprofen (Compound) resembles Naproxen (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Agomelatine (Compound) and Agomelatine (Compound) resembles Naproxen (Compound)